Hopes of slashing the rates of malaria have received a huge boost with a vaccine developed by Oxford University and teamed with Novavax, Inc. and the Serum Institute of India Pvt. Ltd. showing unprecedented levels of efficacy in mid-stage trials in Africa.
Momentous Data For Oxford/Novavax Malaria Vaccine
First To Achieve WHO's 75% Efficacy Goal
A year to the day since the first dose of its COVID-19 vaccine was given, Oxford University's Jenner Institute has unveiled stellar findings from a Phase IIb trial of its malaria vaccine.
More from Clinical Trials
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
The biotech is banking on itolizumab’s longer-term efficacy as well as unmet need in frontline acute graft-versus-host disease as it prepares to meet with the FDA.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
More from R&D
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
A decision from the FDA is due by 28 September.